Novartis has pulled its migraine biologic AIMOVIG (Erenumab) from the November PBAC meeting in response to concerns over the likely reimbursement 'conditions'. …
Listing 'conditions' make Novartis migraine biologic a no-go
October 28, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Merck Healthcare leader joins Brain Cancer Australia charity board
April 30, 2025 - - Latest News -
Icon partners with Nuffield Health for three new cancer centres
April 30, 2025 - - Latest News -
PBS listing for Otsuka and Lundbeck's long-acting injectable for schizophrenia
April 30, 2025 - - Latest News -
PBS listing for Teva's treatment for motor neurone disease
April 30, 2025 - - Latest News -
Government funds new targeted medicine for aggressive lung cancer
April 30, 2025 - - Latest News -
‘Game-changer’ clinical trial launches for Australia’s second-deadliest cancer
April 29, 2025 - - Latest News -
These system-shifting therapies come along every few years, but this is different
April 29, 2025 - - Latest News